Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients.
- Author:
Xiang-hong LI
1
;
Ke-bo ZHONG
;
Yan LIU
;
Ding-hua YANG
;
Jie ZHOU
Author Information
- Publication Type:Clinical Trial
- MeSH: Carcinoma, Hepatocellular; drug therapy; surgery; Female; Humans; Liver Neoplasms; drug therapy; surgery; Liver Transplantation; Male; Neoplasm Recurrence, Local; drug therapy; Niacinamide; analogs & derivatives; therapeutic use; Phenylurea Compounds; therapeutic use; Postoperative Period; Survival Rate; Treatment Outcome
- From: Journal of Southern Medical University 2011;31(9):1608-1610
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the therapeutic effect and safety of Sorafenib in the treatment of tumor recurrence after orthotopic liver transplantation (OLT).
METHODSBetween January, 2009 and June, 2011, 10 patients with tumor recurrence after OLT were treated with Sorafenib (group A) and another 8 recipients received no Sorafenib treatment (group B); 25 patients with hepatocellular carcinoma (HCC) also received Sorafenib treatment (group C). The tumor-bearing survival time, adverse effect and toxicity associated with sorafenib were compared between the 3 groups.
RESULTSIn group A, the median tumor-bearing survival time was 10 months (5-22 months), as compared to 4 months (1-8 months) in group B and 4 months (2-21 months) in group C, showing a significant difference in the survival time among the 3 groups (Kaplan-Meier, log-rank test, P=0.045). No recipient experienced acute graft rejection, but one recipient in group A died due to gastrointestinal bleeding. No significant difference was found in adverse effects associated with Sorafenib between groups A and C (P<0.05).
CONCLUSIONSorafenib can prolong the survival time of patients with tumor recurrence after OLT without increasing the risk of acute graft rejection.
